These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27067848)

  • 1. [Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer].
    Miyata R; Kameyama N; Tomita M; Mitsuhashi H; Baba S; Amada E
    Gan To Kagaku Ryoho; 2016 Mar; 43(3):327-30. PubMed ID: 27067848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
    Nakayama G; Kodera Y; Yokoyama H; Okuda N; Watanabe T; Tanaka C; Iwata N; Ohashi N; Koike M; Fujiwara M; Nakao A
    Int J Clin Oncol; 2011 Oct; 16(5):506-11. PubMed ID: 21431344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
    Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
    Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
    Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
    Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
    BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival.
    Ando K; Emi Y; Miyanari N; Tsuji A; Sakai K; Sawai T; Imamura H; Mori S; Tokunaga S; Oki E; Saeki H; Kakeji Y; Akagi Y; Baba H; Maehara Y; Mori M;
    Int J Clin Oncol; 2020 Jun; 25(6):1115-1122. PubMed ID: 32189156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Induction chemotherapy with S-1/oxaliplatin prevented colostomy in a patient with advanced rectal cancer].
    Shimao K; Yano M; Sasaki K; Goto T
    Gan To Kagaku Ryoho; 2014 Mar; 41(3):395-7. PubMed ID: 24743292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
    Nakamura M; Yamada Y; Muro K; Takahashi K; Baba H; Sasaki Y; Komatsu Y; Satoh T; Mishima H; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Future Oncol; 2015; 11(10):1471-8. PubMed ID: 25963425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
    Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.
    Goldstein D; Mitchell P; Michael M; Beale P; Friedlander M; Zalcberg J; White S; Clarke S
    Br J Cancer; 2005 Mar; 92(5):832-7. PubMed ID: 15756253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).
    Kosugi C; Koda K; Ishibashi K; Yoshimatsu K; Tanaka S; Kato R; Kato H; Oya M; Narushima K; Mori M; Shuto K; Ishida H
    Int J Colorectal Dis; 2018 Jun; 33(6):809-817. PubMed ID: 29484450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer].
    Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1627-32. PubMed ID: 21996957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant chemotherapy comprising modified FOLFOX6 after curative resection of synchronous or metachronous metastasis from colorectal cancer].
    Hatano S; Ishibashi K; Amano K; Ishiguro T; Kuwabara K; Sobajima J; Ohsawa T; Okada N; Kumagai Y; Kumamoto K; Baba H; Tsuji Y; Haga N; Ishida H
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2192-4. PubMed ID: 23268020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment efficacy of surgical management for liver metastasis from colorectal cancer--a report of 198 cases].
    Zhang ZG; Song C; Wang H
    Ai Zheng; 2006 May; 25(5):596-8. PubMed ID: 16687081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
    Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
    Oncology; 2011; 80(1-2):84-91. PubMed ID: 21677451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy].
    Zhou ZG; Pan ZZ; Wan DS; Li LR; Wu XJ; Ding PR; Lin JZ; Peng ZH
    Ai Zheng; 2009 Sep; 28(9):908-12. PubMed ID: 19728905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.